# Targeted Cancer Drugs Using Antibodies and Polymer Scaffolds > This patent describes a new way to deliver powerful cancer drugs directly to tumor cells using a specific antibody attached to a special polymer, aiming to reduce side effects. - **Patent:** US 20210301031 - **Original title:** Napi2b-targeted antibody-drug conjugates and methods of use thereof - **Owner:** Mersana Therapeutics - **Status:** Active - **Times cited:** 3 - **Field:** biotech, pharmaceutical, oncology ## What it does This patent describes a special molecule called an antibody-drug conjugate (ADC) designed to deliver therapeutic agents, which are powerful drugs, directly to cancer cells. The ADC works by using an isolated antibody that specifically attaches to a protein called SLC34A2, also known as NaPi2b, found on the outside of certain tumor cells (Claim 1). Connected to this antibody are one or more "D-carrying polymeric scaffolds." These scaffolds are made of a material called poly(1-hydroxymethylethylene hydroxymethyl-formal) (PHF) and hold the therapeutic agents (D) (Claim 1). The drugs are attached to the scaffold using a "biodegradable bond" (Claim 1), meaning the bond breaks inside the tumor cell, releasing the drug to do its work. For example, this system could deliver a chemotherapy drug directly to a lung cancer cell that has the NaPi2b protein on its surface. ## What it does NOT cover - Does not cover antibody-drug conjugates that target proteins other than SLC34A2 (NaPi2b). - Does not cover ADCs that use a polymeric scaffold different from poly(1-hydroxymethylethylene hydroxymethyl-formal) (PHF). - Does not cover ADCs where the therapeutic agent is not released via a biodegradable bond as described in the claims. - Does not cover ADCs where the total number of polymer scaffolds connected to the antibody is more than 10 (Claim 1). - Does not cover ADCs where the antibody does not have the specific amino acid sequences for its binding regions (CDRs) as detailed in Claim 2. ## The clever bit The innovation lies in combining a highly specific antibody that targets the NaPi2b protein on cancer cells with a unique PHF polymeric scaffold. This scaffold can carry multiple therapeutic agents and release them in a controlled manner via biodegradable linkers, ensuring the drug is potent where needed and less toxic elsewhere. ## Real-world examples 1. Mersana Therapeutics' upifitamab rurxolumab (UPK) which targets NaPi2b 2. Antibody-drug conjugates (ADCs) for ovarian cancer treatment 3. Targeted therapies for non-small cell lung cancer 4. Next-generation ADCs with polymer-drug conjugation platforms ## Why it matters Targeted drug delivery, especially for cancer, is crucial because it aims to kill cancer cells while sparing healthy ones, reducing severe side effects. This patent from Mersana Therapeutics focuses on improving this targeting by using a specific antibody and a unique polymer to deliver drugs more effectively. Such advancements are vital for developing new treatments for difficult-to-treat cancers, potentially offering better outcomes for patients. ## Frequently asked questions ### What does Targeted Cancer Drugs Using Antibodies and Polymer Scaffolds cover? This patent describes a new way to deliver powerful cancer drugs directly to tumor cells using a specific antibody attached to a special polymer, aiming to reduce side effects. ### Who owns patent US 20210301031? This patent is owned by Mersana Therapeutics. ### When does this patent expire? This patent is expected to expire on January 20, 2041, when the invention enters the public domain. ### What is patent US 20210301031 cited by? This patent has been cited by 3 later patents that build on its ideas. ### What problem does this patent solve? Targeted drug delivery, especially for cancer, is crucial because it aims to kill cancer cells while sparing healthy ones, reducing severe side effects. This patent from Mersana Therapeutics focuses on improving this targeting by using a specific antibody and a unique polymer to deliver drugs more effectively. Such advancements are vital for developing new treatments for difficult-to-treat cancers, potentially offering better outcomes for patients. ### What does this patent NOT cover? Does not cover antibody-drug conjugates that target proteins other than SLC34A2 (NaPi2b). **Full plain-English explainer:** https://patentbrief.org/patent/us/20210301031/napi2b-targeted-antibody-drug-conjugates-and-methods-of-use-thereof **Original patent:** https://patents.google.com/patent/US20210301031 --- _Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._ ## Related patents Semantically similar inventions in the PatentBrief corpus: - [Making Cancer-Fighting Antibody Drugs Safer with Precise Attachment](https://patentbrief.org/patent/us/12121527/anthracycline-based-antibody-drug-conjugates-having-high-in-vivo-tolerability) — This patent describes a specific way to build antibody-drug conjugates (ADCs) for cancer treatment by precisely attaching chemotherapy drugs to antibodies to make them safer inside the body. - [Targeted Platinum Drugs for Cancer Treatment](https://patentbrief.org/patent/us/9884123/ligand-targeted-molecules-and-methods-thereof) — This patent describes a way to deliver platinum-based cancer drugs directly to tumor cells by attaching them to a special 'ligand' molecule that seeks out cancer cell markers. - [A Stable Recipe for a Cancer-Fighting Antibody Drug](https://patentbrief.org/patent/us/10391181/cyclodextrin-and-antibody-drug-conjugate-formulations) — This patent describes a specific, stable recipe for a cancer-fighting antibody-drug conjugate (ADC) that targets CD33, using cyclodextrin and a lyoprotectant to keep it effective and reduce impurities. - [Targeting Bad Cells with Toxic Antibodies for Cancer and Autoimmune Disease](https://patentbrief.org/patent/us/20210205465/aberrant-cell-restricted-immunoglobulins-provided-with-a-toxic-moiety) — This patent describes special antibodies equipped with a toxic payload that specifically seek out and bind to unique markers on diseased cells, like cancer or autoimmune cells, to destroy them. - [How Genentech's Antibody Targets Cancerous B Cells](https://patentbrief.org/patent/us/9845355/tecentriq-atezolizumab) — This patent describes a specific humanized antibody designed to bind to a protein called CD79b, which is found on the surface of certain cancer cells.